Our biochemical results suggest a potential beneficial role of sclerostin on CVD in T2D patients due to its inverse association with some cardiovascular risk factors such as LDL-c, calcium, and diastolic blood pressure, which are considered the main factors contributing to susceptibility to atherosclerosis. Here, SOST is linked to type 2 diabetes mellitus.